| Abstract |
Objective To analyze the effects of cognitive and functional changes on patients with obstructive sleep apnea hypopnea syndrome after treatment with pidotimod plus montelukast sodium. Methods Eighty-three children with obstructive sleep apnea hypopnea syndrome admitted to our hospital from January 2017 to June 2018 were randomly divided into control group (n=41) and observation group (n=42). Oral administration of montelukast sodium, the observation group increased the combination of Pidotimod treatment, comparing the levels of inflammatory factors, immune function, clinically relevant indicators, anxiety and depression, cognitive function and safety after treatment. Results The levels of IL-6, AHI, TNF-α, A/N, hs-CRP, CD8+, longest apnea time, apnea, SCSA and CDI scores in the observation group were lower than those in the control group, CD3+, CD4+, CD4+. The level of /CD8+, minimum oxygen saturation and LOTCA were higher than those of the control group (P<0.05); the incidence of adverse reactions was higher than that of the control group (P>0.05). Conclusion Pidotimod combined with montelukast sodium can effectively inhibit the inflammatory response of children with obstructive sleep apnea hypopnea syndrome, improve immune function, improve symptoms of children, eliminate anxiety and depression, restore cognitive function, and have high safety. .
|